AKT1 and hepatocellular carcinoma: Mechanistic studies revealed that alisertib inhibited the activation of AURKA–AKT signaling and decreased the level of xanthine and hypoxanthine in HCC-TRCs, establishing its potential as a purine metabolism–targeted strategy to overcome HCC stemness.